The outlook of companies tied to Viagra's legacy presents a challenging investment scenario . While the initial boom generated substantial returns , generic copies have significantly diminished market share . Investing in associated pharmaceutical companies now requires a thorough assessment of patent rights , evolving healthcare shifts , and the p